【摘要】 目的:观察洛铂与紫杉醇联合化疗治疗晚期卵巢癌的近期疗效及不良反应。方法:50例晚期卵巢癌(Ⅲ期或Ⅳ期)患者,其中26例患者采用洛铂+紫杉醇静脉化疗,其中洛铂30 mg/m2,d1天,紫杉醇135～175 mg/m2d1天。24例患者采用顺铂+紫杉醇静脉化疗,其中顺铂25 mg/m2,d1-3天,紫杉醇135～175 mg/m2d1天,2～4个疗程观察疗效。结果:26例洛铂组患者中,完全缓解7例,部分缓解8例,稳定9例,进展2例,有效率为57.7%。24例顺铂组患者中,完全缓解5例,部分缓解8例,稳定6例,进展5例,有效率为54.2%。主要毒副反应为骨髓抑制、骨骼酸痛、神经毒性和脱发。结论:洛铂联合紫杉醇治疗晚期卵巢癌疗效较好,毒副反应可以耐受。更多还原

【Abstract】 Objective:To evaluate the effects of lobaplatin and paclitaxel on treating recurrent advanced ovarian carcinoma and their adverse reactions.Methods:A total of 50 patients(Ⅲ-Ⅳ) with recurrent advanced ovarian carcinoma were enrolled,including 26 cases of lobaplatin+paclitaxel and 24 cases of cisplatin+paclitaxel.Lobaplatin group(lobaplatin+paclitaxel):lobaplatin at a dose of 30 mg/m2 intravenous infusion on d1,and paclitaxel at a dose of 135～175 mg/m2 intravenous infusion on day 1.Cisplatin group(cisplatin+paclitaxel):cisplatin at a dose of 24 mg/m2 intravenous infusion on day1 and paclitaxel at a dose of 135～175 mg/m2 intravenous infusion on d1.The efficacy was evaluated after 2～4 cycles.Results:Lobaplatin group:seven patients achieved complete response(CR),eight pa-tients achieved partial response(PR),nine patients achieved stable disease(SD) and two patients achieved progressed disease(PD).The overall response rate(RR=CR+PR) was 57.7 %.Cisplatin group:five patients achieved CR,eight patients achieved PR,six patients SD and five patients achieved PD.The overall response rate was 54.2 %.The major adverse effects were bone marrow depression,arthralgia,neurotoxicity and alopecia.Conclusion:Combined chemotherapy of lobaplatin and paclitaxel has a good anti-tumor activity and manage-able toxicity on recurrent advanced ovarian carcinoma patients.更多还原